Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Georgia State University Launches New Institute for Biomedical Sciences
  • USA - English


News provided by

Georgia State University

Mar 04, 2014, 00:00 ET

Share this article

Share toX

Share this article

Share toX


Atlanta, Georgia (PRWEB) March 04, 2014 -- Georgia State’s new Institute for Biomedical Sciences has opened with a mission of advancing research that improves human health, as well as educating and training future generations of leading biomedical scientists and health professionals.

In this Q&A with Georgia State research writer LaTina Emerson, founding director Jian-Dong Li talks about the institute and its goals.

'Despite tremendous advances in biological and medical research, significant gaps still exist between basic laboratory research and its clinical applications,' said founding director Jian-Dong Li.

Post this

Q: Why did Georgia State start the Institute for Biomedical Sciences (IBMS)?
A: Despite tremendous advances in biological and medical research, significant gaps still exist between basic laboratory research and its clinical applications. Now more than ever there is an urgent need for bridging basic research to clinical management strategies. To meet this significant challenge and promote translational research from bench to bedside, the interface between the biomedical science disciplines has emerged as one of the most exciting interdisciplinary research fields in science. To significantly and rapidly accelerate Georgia State University as a recognized leader in this area, the Institute for Biomedical Sciences (IBMS) has been established to expand its contribution and efforts to research and education in these areas.

Q: What is the goal for the Institute for Biomedical Sciences?
A: IBMS will be a leading multidisciplinary research and education (degree-granting) institute dedicated to advancing fundamental and innovative biomedical research that improves human health as well as educating and training future generations of leading biomedical scientists and health (non-M.D.) professionals related to biomedical sciences.

Q: What degree and certificate programs will this institute offer?
A: IBMS plans to offer interdisciplinary undergraduate and graduate programs in biomedical sciences leading to the Ph.D., M.S., and B.S. degrees (and certificate programs for health professionals related to biomedical sciences). The program will provide graduate and undergraduate students with world-class educational and research opportunities to prepare for a wide variety of biomedical careers in industry, research, education and medicine.

Q: How will the Institute for Biomedical Sciences affect Atlanta and the state of Georgia?
A: IBMS will leverage the university’s technology licensing and commercialization infrastructure to translate its innovation and discoveries into market. Outcomes will include direct licensing to existing industry as well as the launch of new companies having the potential to develop into platform industries. Given its broader role in a public university, IBMS will also leverage its core strengths to impact public benefit. This may, for example, include the discovery of new compounds or therapeutic strategies that will have a profound impact on infectious diseases or disorders endemic to developing countries without the potential for substantial economic return.

Q: Will the Institute for Biomedical Sciences partner with any Atlanta area, Georgia or national organizations in its research and education efforts?
A: IBMS will not only build a strong research presence in biomedical sciences, but will also foster a unique environment to promote synergistic and interdisciplinary collaboration with units internal to the university, other Georgia and non-Georgia research institutions, major medical centers, private sector (for example, biopharmaceutical, biotech) companies and organizations/foundations, including the Georgia Research Alliance and Georgia Bio, to develop world-class multidisciplinary research and education programs.

Q: What are your responsibilities as founding director of the Institute for Biomedical Sciences?
A: My major responsibilities are to lead a joint effort to establish a leading multidisciplinary research and education (degree-granting) institute dedicated to advancing fundamental and innovative biomedical research that improves human health as well as educating and training future generations of leading biomedical scientists and health professionals related to biomedical sciences.

Q: What research areas will this institute focus on?
A: IBMS will promote interdisciplinary research that drives advances in biomedical sciences through synergistic collaboration, ultimately leading to better patient care. The focus will be on understanding the mechanistic basis for a variety of important human diseases, such as inflammatory, immunologic and infectious diseases, and developing innovative approaches to prevention, diagnosis and treatment.

Q: What university-level research centers will be part of the Institute for Biomedical Sciences? What is the focus of each center?
A: IBMS will initially build on existing strengths in inflammation, immunity and infection, microbial pathogenesis, translational medicine including translational immunology, oncology, and therapeutics and diagnostics related to biomedical sciences.

Q: Are there opportunities for commercial products to be created from research at the institute?
A: There will be ample opportunities for commercial products to be developed from research at IBMS. Examples include development of universal vaccines for flu, novel anti-viral drugs, and new anti-inflammatory agents with fewer side effects.

Q: What types of biomedical careers will the Institute for Biomedical Sciences prepare students for?
A: Previous efforts have mainly focused on providing training in either basic laboratory research or clinical studies and there is a lack of sufficient workers skilled in the translational biomedical sciences field. One of the major goals of IBMS is to provide a world-class interdisciplinary training environment for preparation of technically skilled students who are capable of filling the diverse workforce needs in the biomedical sciences.

Leah Seupersad, Georgia State University, +1 404-413-1354, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.